BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31195416)

  • 1. [Personalised medicine in urothelial bladder cancer].
    Grunewald CM; Niegisch G
    Aktuelle Urol; 2019 Sep; 50(5):502-508. PubMed ID: 31195416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder cancer: clinical practice.
    Rabinowits G; Laber DA
    J Ky Med Assoc; 2009 Apr; 107(4):129-33. PubMed ID: 19419018
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.
    Marchioni M; Nazzani S; Preisser F; Bandini M; Karakiewicz PI
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):377-387. PubMed ID: 29429376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecularly-driven precision medicine for advanced bladder cancer.
    Krabbe LM; Margulis V; Schrader AJ; Shariat SF; Gust KM; Boegemann M
    World J Urol; 2018 Nov; 36(11):1749-1757. PubMed ID: 29948043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
    Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Predictive Value of O
    Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
    Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant M-VAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder.
    Simon SD; Srougi M
    Prog Clin Biol Res; 1990; 353():169-74. PubMed ID: 2217415
    [No Abstract]   [Full Text] [Related]  

  • 14. The molecular limitations of biomarker research in bladder cancer.
    Vlachostergios PJ; Faltas BM
    World J Urol; 2019 May; 37(5):837-848. PubMed ID: 30171455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group.
    Splinter TA; Scher HI; Denis L; Bukowski R; Soloway M; Vogelzang N; Klimberg I; Dalesio O; Herr H
    Prog Clin Biol Res; 1990; 353():219-24. PubMed ID: 2217422
    [No Abstract]   [Full Text] [Related]  

  • 16. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced and metastatic bladder cancer.
    Dreicer R
    Curr Treat Options Oncol; 2001 Oct; 2(5):431-6. PubMed ID: 12057106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy for urothelial cancer of the bladder--update 2012].
    Niegisch G; Lorch A; Albers P
    Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.